THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC
LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT
VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL
BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.
04 October
2024
Graft Polymer Selects Eurofins Discovery for Pharmacology Testing
in Joint Pre-Clinical Programme
Graft Polymer (UK) Plc (LON: GPL)
(the "Company"), an innovative biotechnology company co-developing
therapeutics for mental health disorders, is pleased to announce
the selection of Eurofins Discovery ("Eurofins") to carry out
initial pharmacology testing for its co-lead aminoindane series.
This testing will begin immediately.
This programme is being developed
under the collaboration agreement with Awakn Life Sciences Corp.
(CSE: AWKN, OTCQB: AWKNF) ("Awakn"), which was first announced on
18 July 2024. The focus of this joint programme is the development
of next-generation medicines targeting trauma-related mental health
conditions, such as Post-Traumatic Stress Disorder ("PTSD"), a
condition affecting approximately 13 million adults in the U.S. and
20 million individuals across the US, UK, and key European
markets.
Eurofins Discovery, a leading global
provider of drug discovery products and services, will conduct
tests on Graft Polymer's co-lead aminoindane series, specifically
assessing its potential for serotonin, dopamine, and noradrenaline
reuptake inhibition. This phase marks a significant milestone in
the programme, following the successful synthesis of the co-lead
series, as announced on 28 August 2024.
Anthony Tennyson CEO of Graft
Polymer, commented: "We are
pleased with this development, Eurofins is an industry leader in
drug discovery research. This marks an important step in our
mission to bring new and innovative solutions to those suffering
from trauma-related mental health disorders like PTSD. The
expertise of Eurofins, combined with our collaborative approach
with Awakn, puts us in an excellent position to advance this
pre-clinical programme swiftly and effectively."
Professor David Nutt, Senior
Scientific Advisor at Graft Polymer, added: "The aminoindane series being developed shows
great promise in modulating key neurotransmitter systems involved
in mental health conditions like PTSD. By targeting serotonin,
dopamine, and noradrenaline reuptake, this pharmacological testing
could unlock new therapeutic pathways for addressing trauma-related
disorders. We look forward to seeing the outcomes of this crucial
pre-clinical stage."
Enquiries:
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director.
anthonytennyson@graftpolymer.co.uk
Allenby Capital (Broker) +44 (0)
20 3328 5656
Nick Naylor /
Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc is an
innovative biotechnology company focused on developing intellectual property relating to the treatment of
mental health and substance use disorders, and the co-development
of therapeutics for mental health disorders. Our mission is to improve outcomes for individuals
suffering from these conditions, with an initial focus on
trauma-related mental health disorders, such as PTSD, which affects
approximately 13 million adults in the U.S. and 20 million in US,
UK, and key EU markets.
For more information, please visit
www.graftpolymer.co.uk.